$1.3B Keytruda windfall will be used to accelerate translational drug R&D in the UK
Translational research in the UK is getting a major boost.
The nonprofit LifeArc has struck a deal to sell a large block of its Keytruda …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
